Jonathan Behr
Partner @ Dementia Discovery Fund
Cambridge, United States
Jonathan Behr is a Series A investor at Dementia Discovery Fund in Cambridge focused on Health Care and Therapeutics. Jonathan Behr is the Partner of Dementia Discovery Fund.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Jonathan Behr invests in
Stages Jonathan Behr invests in
Countries Jonathan Behr invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 5 (56%)
- Therapeutics 5 (56%)
- Biotechnology 5 (56%)
- Medical 3 (33%)
- Biopharma 3 (33%)
Stage
- Series A 3 (33%)
- Series B 2 (22%)
- Seed 1 (11%)
- Funding Round 1 (11%)
- Venture - Series Unknown 1 (11%)
Country
- United States 6 (67%)
- Canada 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sudo Biosciences
|
Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class. | $30M / Series B / Feb 13, 2024 | |
Violet Therapeutics
|
Violet Therapeutics is a healthcare company that operates in stealth mode. | $10.6M / Seed / May 05, 2023 | |
QurAlis
|
QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $88M / Series B / Mar 09, 2023 | |
Nitrase Therapeutics
|
Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications. | $7M / Series A / Nov 02, 2021 | |
|
QurAlis
|
QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $42M / Series A / May 13, 2020 | |
|
Nitrase Therapeutics
|
Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications. | $38M / Series A / Apr 22, 2020 | |
Inversago Pharma
|
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $7M / Series A / Jul 25, 2018 | |
Diasome Pharmaceuticals
|
Diasome Pharmaceuticals is a clinical stage diabetes therapeutics company that designs and develops insulin-based therapies. The company’s products include Oral HVD-I, a targeted oral insulin in a pill or gel cap dose form; HDV-I, an injectable short acting insulin; and HDV-B, an injectable basal long acting insulin. It develops products forpatients suffering from Type 1 and Type 2 diabetes. Diasome Pharmaceuticals was founded in 2004 and is based in Conshohocken, Pennsylvania. | $30M / Venture - Series Unknown / Jul 05, 2017 | |
Tetragenetics
|
Tetragenetics is an early-stage biotechnology company meeting the needs of customers who seek a cost-effective alternative platform technology for the production of genetically engineered proteins. Their technology is particularly well suited to the production of eucaryotic membrane and secretory proteins that are difficult to express inconventional systems. Such proteins include vaccine antigens, monoclonal antibodies, and a variety of therapeutic proteins for the treatment and prevention of human and animal disease. |
Co-Investors
About Dementia Discovery Fund
The Dementia Discovery Fund is the world’s largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease.The DDF has raised a total of £250 million to develop novel disease-modifying therapeutics for all forms of dementia.They have a mandate to validate novel hypotheses andexpand the breadth of targets and mechanisms in development for dementia over the 15 year life of the fund.This enables the DDF to invest in truly novel, early-stage projects starting from target identification, and explore novel biological insights for translation into disease-modifying drugs.
Dementia Discovery Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Angus Grant
Chief Executive Officer
|
|||
Barbara Tate
Chief Strategy Officer
|
|||
|
Jonathan Behr
Partner
|
|||
Jonathan Behr
Partner
|
|||
Damian Crowther
Entrepreneur In Residence
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jonathan Behr invest in?
Jonathan Behr invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jonathan Behr?
Public channels for Jonathan Behr include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jonathan Behr last invest?
The most recent investment recorded for Jonathan Behr closed in Feb 2024. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
